Hikma Pharmaceuticals and Vectura codevelopment and commercialization of GSK's Breo Ellipta generics • NCK Pharma
Drug Delivery to the Lungs 20
Vectura agrees $1.4bn takeover by private equity group Carlyle | pharmaphorum
Vectura Agrees £958m Takeover Following Hikma Advair Launch :: Generics Bulletin
Inhaled Product Development for Inhalers, Nebulisers & Nasal Sprays - Vectura
Vectura to merge with SkyePharma in £441m deal - PMLiVE
Assessing New Technologies in Aerosol Medicine: Strengths and Limitations | Respiratory Care
Hikma and Vectura collaborate to develop GSK generics
Vectura, Sandoz gets favourable ruling in inhaler packaging case against GSK | Euronews
Track Record - Vectura
Adapting Inhaled Medication Practice in COPD and Asthma to Avoid Funding the Tobacco Industry. - Document - Gale Academic OneFile
Propeller Health Receives FDA Clearance For The Propeller Platform In Association With GSKs Ellipta Inhaler
Propeller Health, Vectura ink collaborative connected-inhaler deal - MassDevice
How Much Does Breo Ellipta Cost? - PricePro Pharmacy
Hikma and Vectura to Produce Generic Versions of GSK's Ellipta Meds - Pharmaceutical Processing World
Inhalers listed in the Vectura accounts as generating revenue, or... | Download Scientific Diagram
Vectura's Inhaler Sales May Suffer Over Philip Morris Backlash - Bloomberg
Adapting Inhaled Medication Practice in COPD and Asthma to Avoid Funding the Tobacco Industry. - Abstract - Europe PMC
Vectura Group, Hikma In Global Alliance | Contract Pharma
Vectura, Hikma team up to develop generic versions of GSK's Ellipta
Philip Morris takeover of Vectura denounced by COPD Foundation
Vectura wins additional $10m patent damages against GSK
